# CAN-PRIME **Entity class:** Concept or analytic term **Type:** Clinical study **Collection:** [[collections/Neurotech|Neurotech]] **Primary source:** [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] ## Definition CAN-PRIME is the Canadian expansion of Neuralink's implant clinical program named in the annual report. ## Relationships [[wiki/CAN-PRIME|CAN-PRIME]] is related to [[wiki/Neuralink|Neuralink]], [[wiki/N1 Link|N1 Link]], and the Canadian clinical expansion of the PRIME program. <!-- BEGIN HUMANIZED RELATIONSHIPS 2026-09-11 --> This entry's documented connections are expressed in its definition and related-work routes, with provenance retained in the source-linked material. <!-- END HUMANIZED RELATIONSHIPS 2026-09-11 --> ## Source route [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] · [[collections/Neurotech|Neurotech]] ## Related Work in the Corpus <!-- BEGIN HUMANIZED CORPUS ROUTES 2026-09-11 --> - In [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]], **Neuralink: Operational Clinical Program and Regulatory Trajectory** provides the narrative context for **CAN-PRIME**: In June 2025, Neuralink closed a \$650 million Series E funding round, valuing the company at approximately \$9 billion. <!-- END HUMANIZED CORPUS ROUTES 2026-09-11 -->